Table 2 Comparison of baseline characteristics between sustained responder and recurrence
Characteristic | Sustained responder group | Recurrence group | P value |
|---|---|---|---|
Patients enrolled, n | 85 | 16 | |
Male gender, n (%) | 47 (55.29%) | 10 (62.50%) | 0.723 |
Age (years) | 39.95 ± 8.90 | 39.81 ± 10.86 | 0.956 |
HBV DNA undetectable (< 50 IU/ml), n (%) | 66 (77.65%) | 13 (81.25%) | 0.749 |
HBV DNA detectable (> 50 IU/ml), n (%) | 19 (22.35%) | 3 (18.75%) | |
HBsAg (IU/ml) | 46.52 (4.88, 218.9) | 57.12 (3.91, 286.2) | 0.790 |
HBsAg < 10 IU/ml, n (%) | 28 (32.94%) | 5 (31.25%) | |
HBsAg 10 ~ 100 IU/ml, n (%) | 27 (31.77%) | 5 (31.25%) | |
HBsAg 100 ~ 1000IU/ml, n (%) | 25 (29.41%) | 4 (25.00%) | |
HBsAg > 1000 IU/ml, n (%) | 5 (5.88%) | 2 (12.50%) | |
HBeAg positive, n (%) | 5 (5.88%) | 0 (0.00%) | 0.319 |
IHC with PEG-IFN-α-2b monotherapy, n (%) | 23 (27.06%) | 8 (50.00%) | 0.421 |
CHB with PEG-IFN-α-2b add-on NAs therapy, n (%) | 62 (72.94%) | 8 (50.00%) | |
ETV, n (%) | 38 (61.30%) | 4 (50.00%) | |
TDF, n (%) | 14 (22.58%) | 3 (37.50%) | |
TAF, n (%) | 5 (8.06%) | 1 (12.50%) | |
TMF, n (%) | 5 (8.06%) | 0 (0.00%) | |
Blood routine test | |||
White blood cells (×109/L) | 5.25 ± 1.37 | 5.50 ± 1.55 | 0.515 |
Neutrophils (×109/L) | 3.13 ± 0.96 | 3.18 ± 1.27 | 0.873 |
Platelets (×109/L) | 202.4 ± 54.97 | 220.7 ± 69.98 | 0.245 |
Red blood cells (×1012/L) | 4.92 ± 0.57 | 4.87 ± 0.44 | 0.718 |
Hemoglobin (g/L) | 149.4 ± 19.56 | 144.6 ± 18.91 | 0.368 |
Liver function | |||
ALT (U/L) | 22.00 (15.50, 30.50) | 24.00 (16.00, 32.00) | 0.909 |
AST (U/L) | 22.00 (18.50, 26.00) | 20.00 (18.00, 26.00) | 0.291 |
T-BIL (µmol/L) | 16.60 (10.65, 22.25) | 13.30 (10.20, 16.50) | 0.172 |
Total protein (g/L) | 73.61 ± 8.38 | 72.59 ± 6.78 | 0.667 |
Albumin (g/L) | 49.08 ± 3.20 | 47.32 ± 4.08 | 0.071 |
Globulin (g/L) | 25.40 ± 3.29 | 25.46 ± 3.20 | 0.943 |